替考拉宁在健康受试者静脉给药后的组织穿透情况。
Tissue penetration of telavancin after intravenous administration in healthy subjects.
作者信息
Sun Heather K, Duchin Kenneth, Nightingale Charles H, Shaw Jeng-Pyng, Seroogy Julie, Nicolau David P
机构信息
Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA.
出版信息
Antimicrob Agents Chemother. 2006 Feb;50(2):788-90. doi: 10.1128/AAC.50.2.788-790.2006.
Abstract
The pharmacokinetic disposition of telavancin administered 7.5 mg/kg of body weight every 24 h was determined in plasma and skin blister fluid. The mean penetration of telavancin into blister fluid was 40%. This study reveals that adequate concentrations are achieved in both plasma and blister fluid for pathogens frequently implicated in skin and soft tissue infections.
摘要
测定了每24小时给予7.5mg/kg体重替考拉宁后的药代动力学特征，样本来自血浆和皮肤水疱液。替考拉宁渗入水疱液的平均渗透率为40%。本研究表明，对于皮肤和软组织感染中常见的病原体，血浆和水疱液中均可达到足够的浓度。
相似文献
1
Tissue penetration of telavancin after intravenous administration in healthy subjects.替考拉宁在健康受试者静脉给药后的组织穿透情况。
Antimicrob Agents Chemother. 2006 Feb;50(2):788-90. doi: 10.1128/AAC.50.2.788-790.2006.
2
Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects.健康男性和女性受试者静脉注射替拉万星的多剂量药代动力学
J Antimicrob Chemother. 2008 Oct;62(4):780-3. doi: 10.1093/jac/dkn273. Epub 2008 Jun 26.
3
Pharmacokinetics of dalbavancin in plasma and skin blister fluid.达巴万星在血浆和皮肤疱液中的药代动力学。
J Antimicrob Chemother. 2007 Sep;60(3):681-4. doi: 10.1093/jac/dkm263. Epub 2007 Jul 12.
4
Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin.中度肝功能损害对替拉凡星药代动力学的影响。
Pharmacotherapy. 2010 Jan;30(1):35-42. doi: 10.1592/phco.30.1.35.
5
A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure.健康人群中替考拉宁静脉给药的群体药代动力学模型，用于评估组织暴露情况。
Naunyn Schmiedebergs Arch Pharmacol. 2019 Sep;392(9):1097-1106. doi: 10.1007/s00210-019-01647-w. Epub 2019 May 6.
6
Tissue pharmacokinetics of telavancin in healthy volunteers: a microdialysis study.替考拉宁在健康志愿者体内的组织药代动力学：一项微透析研究。
J Antimicrob Chemother. 2016 Nov;71(11):3179-3184. doi: 10.1093/jac/dkw269. Epub 2016 Jul 11.
7
Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.替考拉宁与其他糖肽类药物的临床药代动力学和药效学比较。
Clin Pharmacokinet. 2018 Jul;57(7):797-816. doi: 10.1007/s40262-017-0623-4.
8
[Skin penetration of sulfamethoxazole and trimethoprim after oral administration].口服给药后磺胺甲恶唑和甲氧苄啶的皮肤渗透情况
Ann Acad Med Stetin. 2002;48:59-73.
9
An interspecies extrapolation of the pharmacokinetics of telavancin, a rapidly bactericidal, concentration-dependent antibiotic.替考拉宁（一种快速杀菌、浓度依赖性抗生素）药代动力学的种间外推。
Xenobiotica. 2011 Jan;41(1):82-9. doi: 10.3109/00498254.2010.525261. Epub 2010 Oct 15.
10
Effect of telavancin on human intestinal microflora.泰利霉素对人体肠道菌群的影响。
Int J Antimicrob Agents. 2011 Dec;38(6):474-9. doi: 10.1016/j.ijantimicag.2011.08.012. Epub 2011 Oct 6.
引用本文的文献
1
Population pharmacokinetic analyses for telavancin using data from healthy subjects and patients with infections.利用健康受试者和感染患者的数据进行替拉万星的群体药代动力学分析。
Antimicrob Agents Chemother. 2025 Jul 2;69(7):e0138224. doi: 10.1128/aac.01382-24. Epub 2025 Jun 12.
2
Pharmacokinetics and pharmacodynamics of peptide antibiotics.肽类抗生素的药代动力学和药效学。
Adv Drug Deliv Rev. 2022 Apr;183:114171. doi: 10.1016/j.addr.2022.114171. Epub 2022 Feb 18.
3
Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment.生理药代动力学模型在预测肾功能损害肥胖患者替拉万星药代动力学中的应用。
Eur J Clin Pharmacol. 2021 Jul;77(7):989-998. doi: 10.1007/s00228-020-03072-y. Epub 2021 Jan 15.
4
A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure.健康人群中替考拉宁静脉给药的群体药代动力学模型，用于评估组织暴露情况。
Naunyn Schmiedebergs Arch Pharmacol. 2019 Sep;392(9):1097-1106. doi: 10.1007/s00210-019-01647-w. Epub 2019 May 6.
5
Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.替考拉宁与其他糖肽类药物的临床药代动力学和药效学比较。
Clin Pharmacokinet. 2018 Jul;57(7):797-816. doi: 10.1007/s40262-017-0623-4.
6
Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.特拉万星：一种新型半合成脂糖肽类药物，用于应对耐革兰氏阳性病原体的挑战。
Ther Adv Infect Dis. 2017 Mar;4(2):49-73. doi: 10.1177/2049936117690501. Epub 2017 Mar 8.
7
Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function.替拉万星在伴有不同程度肾功能损伤的复杂性皮肤和皮肤软组织感染患者中的药代动力学和药效学。
Antimicrob Agents Chemother. 2012 Apr;56(4):2062-6. doi: 10.1128/AAC.00383-11. Epub 2012 Jan 17.
8
Population pharmacokinetics of telavancin in healthy subjects and patients with infections.泰利霉素在健康受试者和感染患者中的群体药代动力学。
Antimicrob Agents Chemother. 2012 Apr;56(4):2067-73. doi: 10.1128/AAC.05915-11. Epub 2012 Jan 17.
9
Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections.泰利万星，一种新型糖肽类抗菌药物，用于治疗复杂性皮肤和软组织感染。
Infect Drug Resist. 2011;4:87-95. doi: 10.2147/IDR.S5327. Epub 2011 Mar 10.
10
本文引用的文献
1
Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.替加环素与标准疗法治疗革兰氏阳性菌所致复杂性皮肤及软组织感染的对比研究
Clin Infect Dis. 2005 Jun 1;40(11):1601-7. doi: 10.1086/429914. Epub 2005 Apr 28.
2
Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations.多次静脉给药后健康受试者血清和皮肤水疱液中替加环素的药代动力学特征。
Antimicrob Agents Chemother. 2005 Apr;49(4):1629-32. doi: 10.1128/AAC.49.4.1629-1632.2005.
3
Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.新型杀菌剂达托霉素（TD-6424）对革兰氏阳性菌的药效学
Antimicrob Agents Chemother. 2004 Aug;48(8):3043-50. doi: 10.1128/AAC.48.8.3043-3050.2004.
4
In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp.新型半合成糖肽类药物特拉万星（TD-6424）、万古霉素、达托霉素、利奈唑胺以及四种对照药物对厌氧革兰氏阳性菌和棒状杆菌属的体外活性
Antimicrob Agents Chemother. 2004 Jun;48(6):2149-52. doi: 10.1128/AAC.48.6.2149-2152.2004.
5
Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria.替考拉宁（TD-6424）的体外比较活性，一种对革兰氏阳性菌具有多种作用机制的快速杀菌、浓度依赖性抗感染药物。
J Antimicrob Chemother. 2004 May;53(5):797-803. doi: 10.1093/jac/dkh156. Epub 2004 Mar 17.
6
Managing skin and soft tissue infections: expert panel recommendations on key decision points.皮肤及软组织感染的管理：关键决策点的专家小组建议
J Antimicrob Chemother. 2003 Nov;52 Suppl 1:i3-17. doi: 10.1093/jac/dkg466.
7
Semi-synthetic glycopeptide antibacterials.半合成糖肽类抗菌剂。
Bioorg Med Chem Lett. 2003 Dec 1;13(23):4165-8. doi: 10.1016/j.bmcl.2003.08.067.
8
In vitro activity of TD-6424 against Staphylococcus aureus.TD-6424对金黄色葡萄球菌的体外活性。
Antimicrob Agents Chemother. 2003 Nov;47(11):3602-4. doi: 10.1128/AAC.47.11.3602-3604.2003.
9
Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy.美国和欧洲引起皮肤及软组织感染的细菌的流行病学及抗生素敏感性：合理抗菌治疗指南
Int J Antimicrob Agents. 2003 Oct;22(4):406-19. doi: 10.1016/s0924-8579(03)00154-7.
10
Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000).从皮肤和软组织感染中分离出的病原体的发生情况及抗菌药物敏感性模式：哨兵抗菌监测项目报告（美国和加拿大，2000年）
Diagn Microbiol Infect Dis. 2003 Apr;45(4):287-93. doi: 10.1016/s0732-8893(02)00543-6.
Zotero 插件